News & Press

contact

print

NUVISAN and ALS Limited sign strategic partnership to open new markets

PRESS RELEASE| BERLIN | BRISBANE
28.07.2021

The NUVISAN group, a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO), and ALS Limited, a global company in the testing, inspection and certification business, today announced the signing of a long term strategic partnership to open new markets. ALS Limited invests into a 49% stake of the NUVISAN group to expand its life sciences portfolio. The global testing specialist with its headquarters in Brisbane/ Australia supports NUVISAN's expansion strategy with its worldwide network.

read complete press release | english version | PDF | 147 KB

NUVISAN und ALS Limited unterzeichnen strategische Partnerschaft zur Erschließung neuer Märkte

PRESSE MITTEILUNG| BERLIN | BRISBANE
28.07.2021

Die NUVISAN-Gruppe, ein internationaler Dienstleister im Bereich der Laborservices, klinischen Studien (CRO/ Clinical Research Organization) und der Auftragsfertigung von Arzneimitteln (CDMO/ Clinical Drug Manufacturing Organization) und die börsennotierte ALS Limited, ein globales Unternehmen im Test-, Inspektions- und Zertifizierungsgeschäft, gaben heute die Unterzeichnung einer langfristigen strategischen Partnerschaft zur Erschließung neuer Märkte bekannt. ALS Limited investiert in eine 49%-Beteiligung der NUVISAN-Gruppe, um ihr Life-Science-Portfolio zu erweitern. Der globale Testing-Spezialist mit Hauptsitz in Brisbane/Australien unterstützt mit seinem weltweiten Netzwerk die Expansionsstrategie von NUVISAN.

Komplette Pressemitteilung lesen | deutsche Version | PDF | 148 KB

New NUVISAN.COM Website

COMPANY INFORMATION | NEU-ULM | BERLIN
01.07.2021

NUVISAN and Innovation Campus Berlin now virtually gathered
under one roof

We are delighted to officially announce the launch of our brand new website, www.nuvisan.com, providing our visitors with an easier way to learn about all NUVISAN’s solutions from the early drug discovery with target identification to the proof of concept in patient.

read complete announcement | PDF | 104 KB

ERS GENOMICS and NUVISAN ICB SIGN CRISPR/Cas9 LICENCE AGREEMENT

PRESS RELEASE | BERLIN
19.04.2021

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

read complete press release | PDF | 156 KB

COVID-19 PANDEMIC - UPDATE

COMPANY INFORMATION | BERLIN | NEU-ULM
17.11.2020

Since the late 2019 onset of Coronavirus in Asia, NUVISAN’s management has been following the development of the disease, assessing its potential impact and anticipated precautionary measures to make sure employees are safe and to secure business continuity.

read complete announcement | PDF | 461 KB

INNOVATION CAMPUS BERLIN is part of the EU supported progamme CARE (Corona Accelerated R&D in Europe)

PRESS RELEASE | BERLIN | NEU-ULM
18.08.2020 English Version

INNOVATION CAMPUS BERLIN is a proud Partner of Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats which is launched today in cooperation with the European Union, the European Federation of Pharmaceutical Industries,  Associations (EFPIA) companies and IMI-Associated Partners.

read complete press release | PDF | 899 KB

INNOVATION CAMPUS BERLIN ist Partner des EU unterstützen Programms CARE (Corona Accelerated R&D in Europe)

PRESSEMITTEILUNG | BERLIN | NEU-ULM
18.08.2020

INNOVATION CAMPUS BERLIN ist stolzer Partner von Europas größter Initiative zur Beschleunigung der Therapieentwicklung für COVID-19 und zukünftige Coronavirus-Ausbrüche. Das CARE Programm wird von der Europäischen Union (EU) sowie der europäischen „Innovative Medicines Initiative“ (IMI) unterstützt und ist das größte Projekt dieser Art zur Erforschung und Entwicklung dringend benötigter neuer Behandlungsmöglichkeiten für COVID-19

Komplette Pressemitteilung herunterladen | PDF | 1.023 KB

NUVISAN starts the „INNOVATION CAMPUS BERLIN“ (ICB) with over 400 workplaces

PRESS RELEASE | BERLIN | NEU-ULM
01.07.2020

On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership.

read complete press release | PDF| 472 KB

NUVISAN startet den „INNOVATION CAMPUS BERLIN“ (ICB) mit über 400 Arbeitsplätzen

PRESSEMITTEILUNG | BERLIN | NEU-ULM
01.07.2020

Am 1. Juli öffnet offiziell der „INNOVATION CAMPUS BERLIN“ (ICB) der Neu-Ulmer NUVISAN. NUVISAN hat von der Bayer AG einen großen Teil der in Berlin ansässigen Pharmaforschung auf dem Gebiet kleinmolekularer Wirkstoffe übernommen und eine strategische Partnerschaft vereinbart.

Komplette Pressemitteilung herunterladen | PDF | 477 KB

NUVISAN und Bayer schaffen neue Forschungseinheit in Berlin

PRESSEMITTEILUNG | BERLIN | NEU-ULM
11.02.2020

Das Pharma-Service Unternehmen NUVISAN hat mit Bayer die Übernahme eines großen Teils der in Berlin ansässigen Pharmaforschung auf dem Gebiet kleinmolekularer Wirkstoffe vereinbart und komplettiert damit sein Leistungsspektrum auf dem Gebiet der präklinischen Forschung.

Komplette Pressemitteilung herunterladen | PDF | 453 KB

Related Topics

close

This service is only available in the desktop version.

Our Services & Solutions along
the Drug Development Value Chain

Please click and choose a category

Discovery

PRECLINICAL

Clinical Phase I

Clinical Phase II

Overall Services

NUVISAN Overall Services along the Value Chain

API Manufacturig
(Non-GMP / GMP)

Formulation
Development

Pharmaceutical
Analysis

Bioanalysis
(Discovery and Regulated)

Biomarkers
(exploratory & GxP)

Translational
Pharmacology

Healthy Volunteers
& Patient Studies

Clinical Trial
Supplies

Regulatory
Affairs

Backend
Services

Corporate Project
Management

NUVISAN Overall Services along the Value Chain

API Manufacturig
(Non-GMP / GMP)

Formulation
Development

Pharmaceutical
Analysis

Bioanalysis
(Discovery and Regulated)

Biomarkers
(exploratory & GxP)

Translational
Pharmacology

Healthy Volunteers
& Patient Studies

Clinical Trial
Supplies

Regulatory
Affairs

Backend
Services

Corporate Project
Management

NUVISAN Overall Services along the Value Chain

API Manufacturig
(Non-GMP / GMP)

Formulation
Development

Pharmaceutical
Analysis

Bioanalysis
(Discovery and Regulated)

Biomarkers
(exploratory & GxP)

Translational
Pharmacology

Healthy Volunteers
& Patient Studies

Clinical Trial
Supplies

Regulatory
Affairs

Backend
Services

Corporate Project
Management

NUVISAN Overall Services along the Value Chain

API Manufacturig
(Non-GMP / GMP)

Formulation
Development

Pharmaceutical
Analysis

Bioanalysis
(Discovery and Regulated)

Biomarkers
(exploratory & GxP)

Translational
Pharmacology

Healthy Volunteers
& Patient Studies

Clinical Trial
Supplies

Regulatory
Affairs

Backend
Services

Corporate Project
Management

NUVISAN Overall Services along the Value Chain

API Manufacturig
(Non-GMP / GMP)

Formulation
Development

Pharmaceutical
Analysis

Bioanalysis
(Discovery and Regulated)

Biomarkers
(exploratory & GxP)

Translational
Pharmacology

Healthy Volunteers
& Patient Studies

Clinical Trial
Supplies

Regulatory
Affairs

Backend
Services

Corporate Project
Management

NUVISAN Overall Services along the Value Chain

API Manufacturig
(Non-GMP / GMP)

Formulation
Development

Pharmaceutical
Analysis

Bioanalysis
(Discovery and Regulated)

Biomarkers
(exploratory & GxP)

Translational
Pharmacology

Healthy Volunteers
& Patient Studies

Clinical Trial
Supplies

Regulatory
Affairs

Backend
Services

Corporate Project
Management